Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
← catalyst calendarNCT06562907 · readout ≤ 103 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
134estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-28 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Weight Management
Interventions
- Drug: GS-4571
- Drug: Placebo
- Drug: Omeprazole
Primary outcomes
what the primary-completion date above is the date OFSingle-Dose PK Parameter AUCinf of GS-4571
measured Up to 96 hours postdose
Single-Dose PK Parameter Cmax of GS-4571
measured Up to 96 hours postdose
Multiple-Dose Plasma PK Parameter: AUCtau of GS-4571
measured Up to 96 hours postdose
Multiple-Dose Plasma PK Parameter: Cmax of GS-4571
measured Up to 96 hours postdose
Percentage of Participants of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Deaths
measured Day 1 up to 95 days
Percentage of Participants of Treatment-Emergent Laboratory Abnormalities
measured Day 1 up to 95 days
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed